FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074573190> ?p ?o ?g. }

• W2074573190 endingPage "734" @default.
• W2074573190 startingPage "725" @default.
• W2074573190 abstract "Background. Previous analyses of TOP2A and HER2 in the Danish Breast Cancer Coopererative Group (DBCG) trial 89D suggested that TOP2A amplifications and possible also deletions are predictive markers for the effect of adjuvant epirubicin in patients with primary breast cancer. We present an updated and extended statistical analysis, requested for IVD-labeling of TOP2A testing. Material and methods. In the DBCG trial 89D 980 Danish patients were randomly assigned to nine cycles of intravenous CMF (cyclophosphamide, methotrexate, and fluorouracil) or CEF (cyclophosphamide, epirubicin, and fluorouracil). Archival tumor tissue was collected retrospectively from 806 of these patients in a prospectively designed, biological sub-study, and was successfully analyzed for TOP2A aberrations and HER2 status in 773 samples (96%). Recurrence-free survival (RFS) was the primary endpoint. Results. TOP2A aberrations (amplifications and deletions) were significantly associated with shorter RFS (p<0.0001) and overall survival (OS) (p<0.0001). Deleted cases had worse prognosis than amplified cases. In a Cox proportional hazard model TOP2A was an independent prognostic marker for RFS and OS. Patients with amplifications had a 61% reduction in the risk of an event (p=0.002) and a 51% reduction in the risk of death (p=0.01) if allocated to CEF compared to 6% and 10% in TOP2A normal patients. A similar but non-significant trend (p=0.08) was shown in patients with TOP2A deletions. Clear statistical evidence of a differential benefit, favoring CEF among patients with TOP2A aberrations was found for RFS (p=0.02 for interaction) but not for OS (p=0.14 for interaction). Conclusion. In conclusion, this updated analysis of TOP2A aberrations in DBCG trial 89D suggests a differential benefit of adjuvant chemotherapy in patients with primary breast cancer, favoring treatment with epirubicin in patients with TOP2A amplifications, and perhaps deletions. Additional studies are needed to clarify the exact importance of TOP2A deletions on outcome, but deletions have proven to be associated with a very poor prognosis." @default.
• W2074573190 created "2016-06-24" @default.
• W2074573190 creator A5009675722 @default.
• W2074573190 creator A5016294354 @default.
• W2074573190 creator A5019620262 @default.
• W2074573190 creator A5031500387 @default.
• W2074573190 creator A5034630560 @default.
• W2074573190 creator A5061205262 @default.
• W2074573190 creator A5071541231 @default.
• W2074573190 date "2008-01-01" @default.
• W2074573190 modified "2023-10-18" @default.
• W2074573190 title "The value of<i>TOP2A</i>gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D" @default.
• W2074573190 cites W125325141 @default.
• W2074573190 cites W1902528276 @default.
• W2074573190 cites W1961026612 @default.
• W2074573190 cites W1966586745 @default.
• W2074573190 cites W1978331365 @default.
• W2074573190 cites W1980522764 @default.
• W2074573190 cites W1999919183 @default.
• W2074573190 cites W2005265464 @default.
• W2074573190 cites W2030796899 @default.
• W2074573190 cites W2041554215 @default.
• W2074573190 cites W2079548272 @default.
• W2074573190 cites W2096471659 @default.
• W2074573190 cites W2102511280 @default.
• W2074573190 cites W2118034665 @default.
• W2074573190 cites W2119416636 @default.
• W2074573190 cites W2143860386 @default.
• W2074573190 cites W2608351357 @default.
• W2074573190 cites W2953748643 @default.
• W2074573190 cites W4322716809 @default.
• W2074573190 doi "https://doi.org/10.1080/02841860801995396" @default.
• W2074573190 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18465341" @default.
• W2074573190 hasPublicationYear "2008" @default.
• W2074573190 type Work @default.
• W2074573190 sameAs 2074573190 @default.
• W2074573190 citedByCount "102" @default.
• W2074573190 countsByYear W20745731902012 @default.
• W2074573190 countsByYear W20745731902013 @default.
• W2074573190 countsByYear W20745731902014 @default.
• W2074573190 countsByYear W20745731902015 @default.
• W2074573190 countsByYear W20745731902016 @default.
• W2074573190 countsByYear W20745731902017 @default.
• W2074573190 countsByYear W20745731902018 @default.
• W2074573190 countsByYear W20745731902019 @default.
• W2074573190 countsByYear W20745731902020 @default.
• W2074573190 countsByYear W20745731902021 @default.
• W2074573190 countsByYear W20745731902022 @default.
• W2074573190 crossrefType "journal-article" @default.
• W2074573190 hasAuthorship W2074573190A5009675722 @default.
• W2074573190 hasAuthorship W2074573190A5016294354 @default.
• W2074573190 hasAuthorship W2074573190A5019620262 @default.
• W2074573190 hasAuthorship W2074573190A5031500387 @default.
• W2074573190 hasAuthorship W2074573190A5034630560 @default.
• W2074573190 hasAuthorship W2074573190A5061205262 @default.
• W2074573190 hasAuthorship W2074573190A5071541231 @default.
• W2074573190 hasBestOaLocation W20745731901 @default.
• W2074573190 hasConcept C121608353 @default.
• W2074573190 hasConcept C126322002 @default.
• W2074573190 hasConcept C143998085 @default.
• W2074573190 hasConcept C203092338 @default.
• W2074573190 hasConcept C207103383 @default.
• W2074573190 hasConcept C2776694085 @default.
• W2074573190 hasConcept C2776755627 @default.
• W2074573190 hasConcept C2780456651 @default.
• W2074573190 hasConcept C2780835546 @default.
• W2074573190 hasConcept C2781197716 @default.
• W2074573190 hasConcept C44249647 @default.
• W2074573190 hasConcept C50382708 @default.
• W2074573190 hasConcept C530470458 @default.
• W2074573190 hasConcept C535046627 @default.
• W2074573190 hasConcept C55493867 @default.
• W2074573190 hasConcept C71924100 @default.
• W2074573190 hasConcept C86803240 @default.
• W2074573190 hasConceptScore W2074573190C121608353 @default.
• W2074573190 hasConceptScore W2074573190C126322002 @default.
• W2074573190 hasConceptScore W2074573190C143998085 @default.
• W2074573190 hasConceptScore W2074573190C203092338 @default.
• W2074573190 hasConceptScore W2074573190C207103383 @default.
• W2074573190 hasConceptScore W2074573190C2776694085 @default.
• W2074573190 hasConceptScore W2074573190C2776755627 @default.
• W2074573190 hasConceptScore W2074573190C2780456651 @default.
• W2074573190 hasConceptScore W2074573190C2780835546 @default.
• W2074573190 hasConceptScore W2074573190C2781197716 @default.
• W2074573190 hasConceptScore W2074573190C44249647 @default.
• W2074573190 hasConceptScore W2074573190C50382708 @default.
• W2074573190 hasConceptScore W2074573190C530470458 @default.
• W2074573190 hasConceptScore W2074573190C535046627 @default.
• W2074573190 hasConceptScore W2074573190C55493867 @default.
• W2074573190 hasConceptScore W2074573190C71924100 @default.
• W2074573190 hasConceptScore W2074573190C86803240 @default.
• W2074573190 hasIssue "4" @default.
• W2074573190 hasLocation W20745731901 @default.
• W2074573190 hasLocation W20745731902 @default.
• W2074573190 hasOpenAccess W2074573190 @default.
• W2074573190 hasPrimaryLocation W20745731901 @default.
• W2074573190 hasRelatedWork W1970372819 @default.
• W2074573190 hasRelatedWork W1980522764 @default.

• next